Drug Trial Radar · NCT01611974
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
Last checked: Nov 19, 2026Latest source record: Jun 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
120
Actual
Start
Jul 17, 2012
Primary completion
Dec 5, 2014
Study completion Dec 5, 2014
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Jun 5, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess safety, antiviral activity, and pharmacokinetics of different doses of maribavir administered orally for up to 24 weeks for treatment of CMV infections that are resistant or refractory to treatment with ganciclovir/valganciclovir or foscarnet in recipients of stem cell or solid organ transplants.
Conditions
- Cytomegalovirus (CMV)
Interventions
MaribavirDrug
Tablet for oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Confirmed Undetectable Plasma Cytomegalovirus (CMV) Within 6 WeeksTime frame: 6 weeks
- Number of Participants With a Treatment Emergent Adverse Event (TEAE).Time frame: 25 weeks
Locations
32 sites in 1 country. Site status is shown where the registry gives one.
UCLA Medical Center
Los Angeles, California
Stanford University Medical Center
Stanford, California
University of Colorado
Denver, Colorado
Yale University
New Haven, Connecticut
University of Florida
Gainesville, Florida
Tampa General Hospital
Tampa, Florida
Emory University
Atlanta, Georgia
Northwestern University Medical Center
Chicago, Illinois
University of Chicago
Chicago, Illinois
Ochsner Clinic Foundation
New Orleans, Louisiana
Johns Hopkins Hospital
Baltimore, Maryland
Brigham and Women's Hospital
Boston, Massachusetts
University of Massachusetts
Worcester, Massachusetts
University of Michigan
Ann Arbor, Michigan
Henry Ford Health Care System
Detroit, Michigan
University of Minnesota Medical Center
Minneapolis, Minnesota
University of Nebraska
Omaha, Nebraska
Columbia University
New York, New York
Memorial Sloan-Kettering Cancer Center
New York, New York
Duke University Medical Center
Durham, North Carolina
Wake Forest Medical Center
Winston-Salem, North Carolina
Cleveland Clinic Foundation
Cleveland, Ohio
Nationwide Children's Hospital
Columbus, Ohio
University of Pennsylvania
Philadelphia, Pennsylvania
Albert Einstein Medical Center
Philadelphia, Pennsylvania
University of Pittsburg
Pittsburgh, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
Vanderbilt Medical Center
Nashville, Tennessee
Methodist Healthcare System
San Antonio, Texas
University of Utah
Salt Lake City, Utah
University of Washington
Seattle, Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.